Aislinn Antrim, MA, Assistant Managing Editor

The risk for developing the rare neurological condition are low following vaccination, with the FDA noting the benefits of vaccination far outweigh the potential risks.

The approval marks the first nonsteroidal mineralocorticoid receptor antagonist proven to significantly slow chronic kidney disease progression and reduce cardiovascular risk in individuals with chronic kidney disease associated with type 2 diabetes.

Results from the APOLLO trial showed a significant 37% reduction in the risk of progression or death, compared to pomalidomide and dexamethasone alone in patients with multiple myeloma.

The FDA also granted Breakthrough Therapy Designation to tezepelumab for patients with severe asthma without an eosinophilic phenotype in September 2018.

No significant differences were found in blood pressure, blood sugar levels, or kidney function when comparing both medications among patients with type 2 diabetes.

The companies say COVID-19 booster shots may be necessary, although the FDA and CDC have disagreed.

The data show that the maximum tolerated dose of rigosertib in combination with nivolumab was not reached in the 3 cohorts of the trial’s dose-escalation phase in patients with advanced KRAS-positive metastatic lung adenocarcinoma.

The new results add to earlier findings from the EMPEROR-Reduced phase 3 trial, which found that empagliflozin reduced the combined relative risk of cardiovascular death or hospitalization for heart failure by 25% compared to placebo.

The updated label follows controversy surrounding aducanumab’s approval in June 2021, despite hesitation from experts on the drug’s efficacy.

Dollar General’s expansion into health care space will include an increased assortment of cough and cold, dental, nutritional, medical, health aids, and feminine hygiene products in many stores.

Study’s secondary endpoints were also met, including the achievement of endoscopic improvement, histologic-endoscopic mucosal improvement, and corticosteroid-free clinical remission at week 52.

Patients with diabetes treated with liraglutide also saw more weight loss compared with patients in the other arms of the study.

Recurrent C. diff infections were observed in 16% of patients who received bezlotoxumab, compared with 29% of patients who received standard of care alone.

The 5-year overall survival was 18% in the CPX-351 group compared to 8% in the standard chemotherapy group.

CEL-SCI Corporation plans to file for FDA approval in patients with advanced primary squamous cell carcinoma of the head and neck based on these trial results.

The approval is based on results from the phase 2 KEYNOTE-629 trial, which found an objective response rate of 50% in adults with recurrent, metastatic, or locally advanced cutaneous squamous cell carcinoma.

Drugs to treat type 2 diabetes using SGLT2 inhibitors are relatively new, with FDA approvals only within the last decade.

Although researchers identified 3 agents that increased the risk of herpes zoster among patients with psoriasis, they also found 2 therapies that seemed to decrease the risk.

The clinical benefit rate was observed in 16.7% of patients in the balixafortide arm and in 19.6% of patients in the eribulin monotherapy arm.

Study to evaluate the safety and efficacy of talazoparib, an oral PARP inhibitor, in combination with enzalutamide, an androgen receptor inhibitor.

Researchers found an overall response rate of 29.8% in patients treated with 177Lu-PSMA-617, compared to a 1.7% partial response in the standard of care only arm.

Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.

Treatments to stimulate the release of eggs increase estrogen hormone production and can act on breast cells, which has created concern that this could turn the cells cancerous.

The results from the first phase 3 SURPASS trials showed promising results with tirzepatide in patients with type 2 diabetes.

Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Studies show that an increased life expectancy is attributable to growth in gross domestic product, increases in the average years of school, and other social factors.

The small-molecule inhibitors of the SOX 11 oncogene showed promise both as single agents and in combination with ibrutinib.

Improvements in glycemic control were seen as early as 3 months after program implementation and were sustained up to a year with continued program engagement.

Researchers observed improvements in total cholesterol, low-density lipoprotein, triglycerides, and serum gamma glutamyl transferase among patients both with and without diabetes.